Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12419585 | 0.76 | RAB9A (0.58) | RAB9ANPC1HPGDSMN1; SMN2TSHR | |
| SCHEMBL5670474 | 0.76 | RAB9A (0.93) | RAB9ANPC1HPGDSMN1; SMN2TSHR | |
| SCHEMBL11006387 | 0.75 | RAB9A (1.00) | RAB9ANPC1HPGDSMN1; SMN2TSHR | |
| SCHEMBL2190623 | 0.74 | KDM4E (0.51) | RAB9ANPC1KMT2ANOTUM | |
| SCHEMBL3633195 | 0.73 | TDP1 (0.59) | RAB9ASMN1; SMN2L3MBTL1CNR2FLT3 | |
| SCHEMBL30037290 | 0.73 | IDH1 (0.43) | HPGDTSHRCNR2FLT3 | |
| SCHEMBL3512013 | 0.73 | IDH1 (0.43) | HPGDTSHRCNR2FLT3 | |
| SCHEMBL1514536 | 0.70 | FLT3 (0.59) | HPGDCNR2FLT3ALDH1A1LMNA | |
| SCHEMBL3796834 | 0.70 | CYP19A1 (0.58) | RAB9ANPC1HDAC6FLT3MAPK1 | |
| SCHEMBL4296221 | 0.70 | CDC7 (0.53) | CNR2FLT3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102197-B1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2102197-B1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| EP-2102197-A1 | 5-([1,3,4]OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4]THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | Merck Patent GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008086854-A1 | 5-([1,3,4] OXADIAZOL-2-YL)-1H-INDAZOL AND 5-([1,3,4] THIADIAZOL-2-YL)-1H-INDAZOL DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063115-A1 | 5-(1,3,4-OXADIAZOL-2-YL)-1H-INDAZOLE AND 5-(1,3,4-THIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES | SGK2, SGK1, SGK3 | RAB9A 4441/4885NPC1 2386/4885HPGD 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.